Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (216)	5/23/2002 4:34:26 AM
From: nigel bates	Read Replies (1) \| Respond to of 469

OGS appoints new Chief Executive Officer Oxford, UK, 23 May 2002 -- Oxford GlycoSciences Plc (LSE: OGS, Nasdaq: OGSI) is pleased to announce the appointment of David Ebsworth PhD as Chief Executive Officer effective from 1 July 2002. In the interim period, David will become CEO Designate, working alongside Michael Kranda who will stand down at the next Board meeting on 11 July 2002. David, 47, has over 20 years experience within the pharmaceuticals industry. Most recently he was Head of the worldwide Pharmaceutical Business Group of Bayer AG, with sales of Euros 5 billion and 20,000 employees. Bayer AG is one of the leading chemical and pharmaceutical companies worldwide. Prior to that, he was President of Bayer Pharmaceutical Division in North America with responsibility for all functions from research through clinical development, regulatory affairs, sales and marketing, finance and strategy. Previously, he held a number of senior management positions within Bayer in Canada, Europe and the United States. Some of his key achievements were to improve research productivity, establish numerous collaborations with pharmaceutical and biotechnology companies as well as to improve marketing and product lifecycle management. In 2001, he received the Global Citizen Award from the School of Diplomacy and International Relations at Seton Hall University in New Jersey. Kirk Raab, OGS' Chairman, commented: 'We are delighted to appoint a candidate of David's calibre as Chief Executive of OGS. He brings extensive knowledge of the pharmaceutical industry at the highest international level and his expertise will be invaluable to OGS as we move ahead with our pipeline. 'Michael Kranda will leave OGS in mid-July. On behalf of the Board, I would like to thank him for his very considerable contribution towards the development of OGS as one of the leading biotechnology companies in Europe.' David Ebsworth, OGS' new CEO, said: 'OGS' proteomics technologies are world-renowned and have the potential to position the Company at the centre of the next phase of drug discovery and development. My role will be to exploit the Company's enormous potential and I very much look forward to the challenges ahead.' Michael Kranda, OGS' outgoing CEO, said: 'David Ebsworth is exactly the kind of senior pharma executive we were seeking to lead the Company forward in its drive to develop and commercialise the drug discovery opportunities arising from our proteomics and glycobiology expertise. I wish him every success and will work closely with him in the transition period.'